Geron (Nasdaq: GERN) reported that, effective August 17, 2026, it granted stock options for an aggregate 311,250 common shares to six newly hired employees as employment inducements. The options have a $1.53 exercise price, ten-year term, and four-year vesting, and were granted under Nasdaq Listing Rule 5635(c)(4) pursuant to Geron’s 2018 Inducement Award Plan.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The options were granted effective August 17, but the disclosure is an option grant rather than a reported share issuance; if all 311,250 options are exercised, issuing those shares would increase the total share count and reduce existing holders’ percentage ownership.
Market Context
GERN’s prior inducement notice was followed by a 2.84% 24-hour reaction, offering a direct historica...
Analysis
GERN’s prior inducement notice was followed by a 2.84% 24-hour reaction, offering a direct historical comparison. This announcement adds option terms rather than operating data; potential share issuance and retention conditions remain the key considerations.
Key Figures
Shares underlying options:311,250 sharesNewly hired employees:6 employeesExercise price:$1.53 per share+5 more
8 metrics
Shares underlying options311,250 sharesAggregate grant to six newly hired employees
Newly hired employees6 employeesRecipients of inducement stock options
Exercise price$1.53 per shareEqual to the August 17, 2026 closing price
Option term10 yearsTerm of the inducement stock options
Chinmaya Rath joined as Chief Business Officer with over 25 years of biopharma leadership.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The Aug 5 earnings release had the strongest positive reaction, while the July 13 appointment diverged negatively; prior inducement notices were followed by positive reactions.
"granted stock options ... as an inducement material to such employees’ acceptance"
Something offered to persuade someone to act a certain way, such as a payment, gift, rebate, stock award, or other benefit intended to influence decisions. Investors care because inducements can change behavior inside or around a company—affecting costs, sales practices, or management incentives—and can create conflicts of interest or trigger regulatory review. Think of it like a coupon or bonus meant to sway a choice, which can alter expected outcomes for shareholders.
exercise pricefinancial
"The stock options have an exercise price of $1.53 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"have a ten-year term and vest over four years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.53 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
FAQ
What did Geron (GERN) announce on August 18, 2026 regarding stock options?
Geron announced it granted stock options to purchase 311,250 shares of common stock to six newly hired employees, effective August 17, 2026. According to Geron, these inducement grants were approved under Nasdaq Listing Rule 5635(c)(4) with a ten-year term and four-year vesting schedule.
What is the exercise price of the new Geron (GERN) inducement stock options?
The exercise price of the new Geron inducement stock options is $1.53 per share. According to Geron, this price equals the closing market price of Geron’s common stock on the August 17, 2026 grant date, aligning the options’ value directly with the company’s share price at issuance.
How do the Geron (GERN) inducement stock options granted in August 2026 vest?
The Geron inducement stock options vest over four years for each recipient employee. According to Geron, 12.5% of the shares vest on the six-month employment anniversary, with the remaining shares vesting in equal monthly installments over the following 42 months, subject to continued employment.
How many employees received Geron (GERN) inducement stock options and how many shares are covered?
Six newly hired employees received Geron inducement stock options covering 311,250 shares of common stock in total. According to Geron, these equity awards are intended as material inducements to employment and were granted under the company’s 2018 Inducement Award Plan and standard stock option agreement.
Under what plan and Nasdaq rule were Geron (GERN) inducement options granted in August 2026?
The inducement options were granted under Geron’s 2018 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). According to Geron, the Compensation Committee of the Board approved these equity awards, which are subject to the plan’s terms and the company’s form stock option agreement.
